TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02114515

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Hospital usual care
Description: Written discharge instructions provided to patients prior to hospital discharge.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hospital usual care
Description: Written discharge instructions provided to patients prior to hospital discharge.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Navigator intervention
Description: A Patient Navigator will provide social support, literacy appropriate education, and act as a conduit between the patient and the patient's medical team

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-led telephone support line
Description: The peer-led telephone support line will provide social support, peer-to-peer coaching, and facilitate communication with the patient's medical care team.
Study: NCT01661972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine and aflibercept
Description: Capecitabine given on days 1-14 and off days 15-21. Dose: Phase 1 cohort 1 850mg/m2 Phase 1 cohort 2 1000mg/m2, Phase 2 RPTD.~Aflibercept will be held constant at 6 mg/kg, given intravenously every 3 weeks.~Both agents will be administered on a 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine and aflibercept
Description: Capecitabine given on days 1-14 and off days 15-21. Dose: Phase 1 cohort 1 850mg/m2 Phase 1 cohort 2 1000mg/m2, Phase 2 RPTD.~Aflibercept will be held constant at 6 mg/kg, given intravenously every 3 weeks.~Both agents will be administered on a 21-day cycle.
Study: NCT03146026

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Exercise Training
Description: The CET program was performed for 60 minutes with 5 minutes of warm-up and cool-down per day, 3 times a week for 12 weeks. Combined exercise consisted of 20 minutes of various resistant band exercises (Upper body: seated rows, biceps curl, shoulder flexion, elbow flexion, chest press; Lower body: hip flexion, hip extension, calf raise, leg press, squat) and 30 minutes of treadmill walking. The warm-up and cool down consisted of static stretching. Intensity of exercise was gradually increased from 40-50% heart rate reserve (HRR) in weeks 1-4, and to 60-70% HRR in weeks 9-12. Each training session was fully supervised by the researchers. Every subject wore a heart rate monitor during the whole training session so as to maintain the correct training intensity.
Study: NCT01740089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 800-1400 mg/day orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 800-1400 mg/day orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: 800-1400 mg/day orally
Study: NCT03020498

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Fluzone
Description: Influenza Virus Vaccine Suspension for Intramuscular Injection

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Fluzone
Description: Influenza Virus Vaccine Suspension for Intramuscular Injection

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Fluzone
Description: Influenza Virus Vaccine Suspension for Intramuscular Injection

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: FluMist
Description: Influenza Virus Vaccine Live, Intranasal Intranasal Spray

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: FluMist
Description: Influenza Virus Vaccine Live, Intranasal Intranasal Spray
Study: NCT01472159

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CGM Family Teamwork Intervention
Description: The family-focused behavioral intervention targets barriers associated with sustained CGM use in youth with type 1 diabetes. During months 1-18, families in the intervention group will participate in the intervention at each study visit for about an additional 30 minutes.
Study: NCT00506896

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intraarticular injection
Description: Triamcinolone hexacetonide 60mg(3ml)by intraarticular injection Triamcinolone acetonide 60mg (3ml)by intramuscular administration
Study: NCT02060084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: a control group
Description: the same dose of luke warm water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: a probiotic-supplemented group
Description: was orally administered starting from day 2 after birth, at a dose of 0.5g (the numbers of Long Bifidobacterium, Lactobacillus acidophilus and Enterococcus faecalis in live\>0.5\*107CFU), twice per day, for 2 weeks
Study: NCT02751957

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Start Denver Model
Description: The Early Start Denver Model is an evidence based, behavioral intervention for young children who have an autism spectrum disorder. It is a behavioral treatment informed by the principles of applied behavior analysis.
Study: NCT00366470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A. 100,000 IU Cholecalciferol per dose of 3.3ml
Description: 100,000 IU Cholecalciferol in 3.3ml Migliol (Carrier) oil, once every two weeks for 2 Months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: B. Migliol Oil without Cholecalciferol
Description: 3.3 ml Migliol Oil, every two weeks for two months
Study: NCT01171053

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered CBT
Description: Internet-delivered cognitive behavioral therapy with therapist support.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Therapist support
Description: Weekly therapist support without CBT-interventions
Study: NCT04396938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Active Drug Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo Capsule
Study: NCT02068053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] BMS-986020
Study: NCT03958526

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active tDCS
Description: Patients in active group will receive 10 sessions of anodal tDCS delivered over primary motor cortex (M1) contralateral to the most painful side with a constant current of 2 miliAmpers for 20 minutes.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham tDCS
Description: Same protocol (electrode montage,session duration) will be used for sham stimulation. But the device won't be active for full 20 minutes.
Study: NCT02120807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Study: NCT01868061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Lebrikizumab will be administered as SC injection at 125 or 37.5 mg every 4 weeks, for 104 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Lebrikizumab will be administered as SC injection at 125 or 37.5 mg every 4 weeks, for 104 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lebrikizumab
Description: Lebrikizumab will be administered as SC injection at 125 or 37.5 mg every 4 weeks, for 104 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lebrikizumab matching placebo will be administered as SC injection every 4 weeks for 52 weeks.
Study: NCT03864159

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suction cups
Description: The technique will be performed with the subject sitting on the floor, placing the Foam roller on the back of the thigh, requesting the athlete to perform cranial and caudal movements during the established time. The stretching exercise with the Foam roller will be done during 2 minutes in each member. The intervention through the suction cups will be performed with the subject in prone position, on the stretcher. The suckers are placed in the proximal part where the posterior musculature of the leg originates and in the distal part of the biceps femoris, semitendinosus and semimembranous insertion. This administration of the suckers will be applied during a period of 7 minutes in each member.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Foam roller
Description: Each session will last 18 minutes, taking place two days a week, in a period of 4 weeks. The intervention will be carried out before starting the training session. The intervention through the self-administration of Foam roller has the objective of increasing the flexibility of the isquitibial musculature. The technique will be performed with the subject sitting on the floor, placing the Foam roller on the back of the thigh, requesting the athlete to perform cranial and caudal movements during the established time. The stretching exercise with the Foam roller will be done during 2 minutes in each member.
Study: NCT01866800

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Renal Guard
Description: Renal Guard

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Conventional Treatment
Description: Saline and N-acetylcysteine
Study: NCT01563224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo
Study: NCT03438591

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic 4196 lead
Description: Cerclage-CRT pacing with Medtronic 4196 lead (Attain Ability Lead)
Study: NCT01866800

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treatment
Description: Saline and N-acetylcysteine
Study: NCT00841711

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intensive Case Management
Description: Transitions involves the integration of evidence-based interventions, intensive case management that incorporates outreach elements similar to assertive community treatment (ACT). Intensive case management goes beyond the tenets of case management and incorporates community outreach. This model of case management has its roots in assertive community treatment (ACT) and has demonstrated a 37% greater reduction in homelessness and a 26% greater improvement in psychiatric symptom severity compared with standard case management treatments. As such, intensive case management is likely to result in important outcomes for the target population, is evidence-based and has been validated in prison-release programs.
Study: NCT01128322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-Amlodipine, Telmisartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-Amlodipine, Telmisartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-Amlodipine, Telmisartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-Amlodipine, Telmisartan
Study: NCT03815994

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation
Description: This device produces a muscle contraction in response to a externally generated low-voltage electric impulse, which is conducted through electrodes placed on the skin over the muscle group to be stimulated.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Neuromuscular Electrical Stimulation
Description: This device produces a muscle contraction in response to a externally generated low-voltage electric impulse, which is conducted through electrodes placed on the skin over the muscle group to be stimulated.
Study: NCT04596332

Intervention type: OTHER
Intervention: no intervention measures
Description: Because this study was a retrospective study, no intervention measures were implemented for the patients enrolled.

Intervention type: OTHER
Intervention: no intervention measures
Description: Because this study was a retrospective study, no intervention measures were implemented for the patients enrolled.

Intervention type: OTHER
Intervention: no intervention measures
Description: Because this study was a retrospective study, no intervention measures were implemented for the patients enrolled.
Study: NCT01992614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06678552 or Placebo
Description: PF-06678552 or placebo will be administered as an extemporaneously prepared solution once in each period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06678552 or Placebo
Description: PF-06678552 or placebo will be administered as an extemporaneously prepared solution once in each period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06678552 or Placebo
Description: PF-06678552 or placebo will be administered as an extemporaneously prepared solution once in each period.
Study: NCT01128322

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-Amlodipine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-Amlodipine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01211509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: After diagnosis of fBOS every day an oral capsule with 10 mg montelukast of placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Montelukast
Description: After diagnosis of fBOS every day an oral capsule with 10 mg montelukast of placebo
Study: NCT04304170

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VES002
Description: The sachets were to be dissolved in 200 ml of water at room temperature to be taken before breakfast.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The sachets were to be dissolved in 200 ml of water at room temperature to be taken before breakfast.
Study: NCT00712621

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Counseling
Description: • Arm II: Patients receive audio visual aids and weekly counseling sessions by the expert counselors and breast cancer survivors over 8 weeks for a total of 8-16 sessions. Patients receive written materials from the counseling group after the completion of the sessions

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Written materials
Description: • Arm I: Patients receive the support by providing existing resources. Patients receive standard written materials from the counseling group after enrolling in the study.
Study: NCT04206475

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rehabilitation
Description: the rehabilitation program consisted of an intensive treatment lasting 4 weeks, and including 3 daily interventions each working day (5 working days per week, for a total of 20 days of treatment and 60 sessions). The 3 daily sessions were organized as follows:~1 physio-kinesis and/or occupational therapy, 1 speech therapy, and 1 neuro-psychology treatment.~Each session lasted 45 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: rehabilitation
Description: the rehabilitation program consisted of an intensive treatment lasting 4 weeks, and including 3 daily interventions each working day (5 working days per week, for a total of 20 days of treatment and 60 sessions). The 3 daily sessions were organized as follows:~1 physio-kinesis and/or occupational therapy, 1 speech therapy, and 1 neuro-psychology treatment.~Each session lasted 45 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive Memory-Focused Training Program (IM-FTP)
Description: During each session, the patient was engaged in a one-to-one interaction with the therapist. Overall, the treatment targeted the following memory subfunctions: verbal and visuo-spatial short-term memory, verbal and visuo-spatial long-term memory, working memory and procedural memory
Study: NCT02743780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGV354 ophthalmic suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MGV354 placebo
Description: Inactive ingredients used as placebo comparator
Study: NCT04288258

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth-Based Health and Wellness Program (POWERS-TBI)
Description: The treatment program is interactive and will be delivered via the internet, along with ongoing telephone health coaching calls designed to motivate, problem-solve challenges, reinforce skills learned, and prevent relapse.
Study: NCT02696499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA101B
Description: 40 mg PA101B administered via inhalation twice daily for 7 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered via inhalation twice daily for 7 weeks
Study: NCT00976378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX-A12
Description: single ascending IV doses, ranging from 0.05 mg/kg to 10.8 mg/kg
Study: NCT00316797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 123-I INER
Description: Serial whole body planar imaging in the anterior and posterior projection will be performed at 1 min, 30 min, 1 h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, and 18-24h following injection of 5 mCi of 123-I INER. Venous blood data will be acquired at each imaging time point. In addition a 24 hour urine collection will commence following radiotracer injection and urine sampled in five collections every 4 hours collection for first sixteen hours (4 collections), then one collection from 16 to 24 h. Whole body and source organs uptake will be analyzed on anterior and posterior images for calculating the radiation absorbed doses to organs using the MIRD method as described previously (Seibyl, et al, 1993). Plasma and urine metabolites will be characterized and safety assessments obtained.
Study: NCT00976378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX-A12
Description: single ascending IV doses, ranging from 0.05 mg/kg to 10.8 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX-A12
Description: single ascending IV doses, ranging from 0.05 mg/kg to 10.8 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX-A12
Description: single ascending IV doses, ranging from 0.05 mg/kg to 10.8 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX-A12
Description: single ascending IV doses, ranging from 0.05 mg/kg to 10.8 mg/kg
Study: NCT01602302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bDMARD withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept)
Description: bDMARDS (etanercept, adalimumab, infliximab, certolizumab, golimumab, tocilizumab, abatacept) will be discontinued after baseline visit in all participants
Study: NCT02282215

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CLT-008
Description: Single intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CLT-008
Description: Single intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CLT-008
Description: Single intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Daily subcutaneous injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Daily subcutaneous injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Daily subcutaneous injections

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: Daily subcutaneous injections
Study: NCT04034966

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Claria telemedicine device
Description: Use of Claria telemedicine module, which stores patient information in the cloud.
Study: NCT01898299

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: A neurostimulation technique that passes an extremely weak electric current through the brain.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Sham (inactive) tDCS treatment
Study: NCT04337593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: 20mg d1,8, repeated every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: 2500IU/㎡, d1,repeated every 3 weeks
Study: NCT02496559

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pre-consultation CRP
Description: Use of CRP test on all children with fever before the consultation (intervention) compared to where the doctor requests a CRP test (no intervention)
Study: NCT01170936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: canakinumab
Description: Single dose of canakinumab 300mg s.c. injection
Study: NCT00917878

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk
Description: 500 mL low-fat milk added to high-fat meal

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein
Description: Milk protein in 500 mL water added to high-fat meal
Study: NCT00917878

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium
Description: Milk calcium in 500 mL water added to high-fat meal
Study: NCT03477266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosapride
Description: Intake mouthly dissolving mosapride tablets in immediate post cesarean section

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Dummy identical tablets to mouthly dissolving mosapride tablets
Study: NCT01038934

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: samples collected by buccal cytobrush
Study: NCT00976378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX-A12
Description: single ascending IV doses, ranging from 0.05 mg/kg to 10.8 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX-A12
Description: single IV dose, at efficacious dose level
Study: NCT00917878

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control
Description: Lactose in 500 mL water added to high-fat meal
Study: NCT04707027

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept Injection (2 mg/0.05 ml)
Description: Intravitreal aflibercept injections (treat and extend regimen)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Defer treatment
Description: Follow up with fundus photo and OCT every 4 weeks
Study: NCT02485431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deflazacort

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deflazacort
Study: NCT03386747

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home visits to improve parenting behaviors
Description: Caregivers will be visited twice per month starting from the third trimester in pregnancy up to age three to discuss important health and development behaviors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Center based parenting groups
Description: Caregivers will be invited to early childhood development groups. Groups will meet at nearby centers twice per month. Caregivers will be invited to participate starting from the third trimester up to age 3 of the child.
Study: NCT04091984

Intervention type: DIAGNOSTIC_TEST
Intervention: Prospera
Description: No Interventions, this is an observational study.
Study: NCT04200768

Intervention type: OTHER
Group type: OTHER
Intervention: Prospective data and sample collection
Description: Performance of measurements of adiposity, extra collection of blood samples